Health innovations that matter
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncology and hepatology.
Our values
Agility
The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.
Tenacity
There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.
Commitment
We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.
Our commercialized products
Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SV® is approved in the United States while EGRIFTA® is available only in Canada.
